Please provide your email address to receive an email when new articles are posted on . SGLT2 and GLP-1 agents were linked to lower risk of kidney-related outcomes for adults with type 2 diabetes and ...

SGLT2 inhibitors represent one of the most remarkable therapeutic developments in heart failure care, transitioning from ...

This transcript has been edited for clarity. Matthew Sparks, MD: Hi. I'm Dr Matthew Sparks and welcome to Medscape's InDiscussion series on chronic kidney disease. This is episode 1, and today we'll ...

In a real-world study of patients aged 60 years or older with diabetes, SGLT2 inhibitor users experienced a significantly slower decline in estimated glomerular filtration rate compared with DPP4 ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SGLT2 inhibitors ...

Credit: Getty Images Evidence in favor of SGLT2 inhibitors and nonsteroidal mineralocorticoid receptor antagonists for treating patients with diabetic kidney disease is growing. In combination with ...

Patients with type 2 diabetes newly initiated on a sodium-glucose cotransporter-2 (SGLT2) inhibitor did not have an added risk of fracture at 6 months or 1 year compared with patients started on a ...

The final thesis of Professor Lim Soo's team of the Department of Endocrine Metabolism at Bundang Seoul National University ...

Patients with AAV and kidney involvement who take SGLT-2 inhibitors may have a reduced risk for ESRD and kidney transplant ...

Please provide your email address to receive an email when new articles are posted on . SGLT2 inhibition may confer similar kidney and CV outcomes vs. GLP-1 receptor agonists for diabetes. Results ...